

Addario Lung Cancer Consortium

 consortiapedia.fastercures.org/consortia/addario-lung-cancer-consortium/

Research Areas



Tool Development

Clinical Trial, Data Sharing



Biomarker Research

Diagnostic, Disease Progression



Product Development

Drugs

At a Glance

- Status: **Active Consortium**
- Year Launched: **2008**
- Initiating Organization: **Addario Lung Cancer Medical Institute**
- Initiator Type: **Nonprofit foundation**
- Location: **Europe**

Abstract

Addario Lung Cancer Medical Institute (ALCMI) is a patient-centric, international research consortium. ALCMI overcomes barriers to collaboration via a world-class team of investigators from 20+ institutions in the U.S. and Europe, supported by dedicated research infrastructures such as centralized tissue banks and data systems. ALCMI directly facilitates research by combining scientific expertise found at leading academic institutions with patient access through their network of community cancer centers – accelerating novel research advancements to Lung Cancer patients.

Mission

The Foundation's goal is to work with a diverse group of physicians, organizations, industry partners, individuals, patients, survivors, and their families to identify solutions and make timely and meaningful change and turn lung cancer into a chronically managed disease by 2023. Patients fighting Lung Cancer today and those who will be diagnosed tomorrow are at the heart of their mission. Driven by the knowledge that Lung Cancer is the number one cancer killer worldwide annually, their imperative is

to dramatically increase patient survival rate. Their ultimate goal is to be the global leader fighting Lung Cancer and the largest source of non-profit funding dedicated to turning Lung Cancer into a manageable, chronic disease and ultimately, a curable disease.

Consortium History

CASTLE (2010-present): established standardized biorepository with outcomes data for improved understanding of tumor biology, and molecular drivers (free testing). It also serves as a collaboration engine driving discovery, development and delivery of diagnostics, targeted therapies, and immunology agents.

INHERIT EGFR (2012-present): determining prevalence of inherited EGFR T790 mutations (free testing) in lung cancer patients and their first-degree relatives and estimating prevalence of CAT scan detected lung nodules in individuals with inherited mutations and no lung cancer diagnosis

Genomics of Young Lung Cancer (2014-present): facilitating delivery of targeted therapies, characterizing the impact of young age at lung cancer diagnosis on the genomic landscape of lung cancer (free testing), and establishing a prospective registry of biospecimens for investigational acquired and inherited genomics.

Structure & Governance

The Addario Lung Cancer Medical Institute (ALCMI, voiced as “Alchemy”) works in tandem with their partner, the Addario Lung Cancer Foundation (ALCF). ALCMI is patient founded, focused, and funded.

Financing

Since its founding in 2006, the ALCF has grown into the first international collaborative entity of its kind, raising over \$30 million for Lung Cancer research through a variety of fundraising campaigns and

initiatives. ALCMI was founded 2 years later in 2008.

Patent Engagement

Patients benefit by being empowered through more active involvement and participation in advancing discovery, treatment and care for themselves and others. By participating in clinical research and giving researchers access to their biospecimens, clinical data, and therapeutic outcomes, patients will help to accelerate the development of precision medicine for lung cancer.

Links/Social Media Feed

Homepage <http://www.lungcancerfoundation.org/research/alcmi/>

Points of Contact

Steven Young, President & COO / (203) 226-5765 / syoung@alcmi.net

Samantha Cummis, Director of Marketing and Communications,
samantha@lungcancerfoundation.org.

Sponsors & Partners

Astellas Pharma US
Biodesix
Boehringer Ingelheim
Bristol-Myers Squibb
CancerCURE of America

Caris Life Science
Celgene
Genentech – A Member of the Roche Group
GTx
Helsinn
Ignyta
Life Technologies
Palo Alto Medical Foundation – Sutter Health
PenTV
Pfizer Oncology
Project Hope Exchange
RadiologyInfo.org
The Safeway Foundation
SuperDimension

Updated: **06/19/2017**